Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
FLT180a
BIOLOGICAL
2 trials
Sponsors
University College, London
, Spur Therapeutics
Conditions
Hemophilia B
Phase 1
A Factor IX Gene Therapy Study (FIX-GT)
Terminated
NCT03369444
University College, London
Hemophilia B
Start: 2017-12-05
End: 2020-10-20
Updated: 2022-12-02
A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy
Terminated
NCT03641703
Spur Therapeutics
Hemophilia B
Start: 2018-07-10
End: 2023-05-24
Updated: 2023-07-20
Related Papers
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B
New England Journal of Medicine
2022-07-20
144 citations
Factor IX Expression within the Normal Range Prevents Spontaneous Bleeds Requiring Treatment Following FLT180a Gene Therapy in Patients with Severe Hemophilia B: Long-Term Follow-up Study of the B-Amaze Program
Blood
2021-11-05
8 citations
A Single Intravenous Infusion of FLT180a Results in Factor IX Activity Levels of More Than 40% and Has the Potential to Provide a Functional Cure for Patients with Haemophilia B
Blood
2018-11-29
22 citations